Viridian Therapeutics Inc (VRDN)

$20.84 +1.53 (7.92%)
Market Cap 1.99B
Revenue (ttm) 70.85M
Net Income (ttm) -342.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -483.56%
Debt to Equity Ratio 0.08
Volume 2,170,200
Avg Vol 2,000,980
Day's Range N/A - N/A
Shares Out 103.08M
Stochastic %K 98%
Beta 0.91
Analysts Strong Sell
Price Target $36.06

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 103A, Waltham, United States
TheProphitWhisperer
TheProphitWhisperer Aug. 4 at 5:42 PM
$VRDN Will be back at $30 soon
0 · Reply
schmittzi
schmittzi Aug. 4 at 10:43 AM
$VRDN
0 · Reply
Merlintrader
Merlintrader Aug. 4 at 10:03 AM
Viridian Therapeutics (Nasdaq: $VRDN): Complete Stock Hub for FDA-Approved Lumvoa, Elegrobart and the TED Franchise https://www.merlintrader.com/viridian-therapeutics-stock-hub/
0 · Reply
Oldgrape
Oldgrape Aug. 4 at 7:13 AM
$VRDN Payor coverage is on track.. Even mildly ahead on speed I would say based on insurance documents posted as of today. CBS Michigan --> Lumvoa better than Tepezza (no site-of-care requirement & Tepezza has one) Humana IL D-SNP --> both free of step therapy Coordinated Care WA --> same class, same tier, no differential flags Centene Ambetter --> mutual exclusion Kaiser WA -->not yet written + already on PA list for Cigna, United Healthcare etc
3 · Reply
type12
type12 Aug. 3 at 4:35 PM
$VRDN https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/how-positive-elegrobart-reveal-1-phase-iii-data-could-impact
0 · Reply
Oldgrape
Oldgrape Aug. 1 at 7:40 AM
$VRDN I have been reading facebook thyroid eye disease groups and see posts about patients with relapsed TED after TEPEZZA are being approved for Lumvoa. Earnings call should shed more light on this but if this early trend is true, this relapsed segment alone is a bilion plus opportunity that sits outside the active-TED market consensus models with zero competition.
1 · Reply
Grannynani
Grannynani Jul. 31 at 7:24 PM
$SOC $VRDN how I’m feeling rn. Shorted but gettin tall📈
0 · Reply
Grannynani
Grannynani Jul. 31 at 4:08 PM
$SOC greeaaaat 10% pull starting todayyyy📈🙏🏼. $VRDN Ouuu if you was in front of me of me I’d slap the shit out you📉🤨 stop being goofy and invest in the certified biotech who actually has a drug competing and beating a big name pharma👀 and we goin downnnn🤦🏻‍♂️ need a Michael Jackson ahhh slap🕺🏼👋🏼
0 · Reply
TheProphitWhisperer
TheProphitWhisperer Jul. 30 at 3:18 PM
$VRDN Nice consolidation before a breakout in anticipation of the August 4th earnings.
0 · Reply
schmittzi
schmittzi Jul. 30 at 2:44 PM
$VRDN
0 · Reply
Latest News on VRDN
Viridian Therapeutics price target raised to $43 from $32 at Wedbush

2026-06-30T11:50:21.000Z - 5 weeks ago

Viridian Therapeutics price target raised to $43 from $32 at Wedbush

Viridian Therapeutics price target raised to $38 from $35 at Truist

2026-06-30T11:20:59.000Z - 5 weeks ago

Viridian Therapeutics price target raised to $38 from $35 at Truist

Viridian Therapeutics price target raised to $35 from $34 at RBC Capital

2026-06-30T11:11:03.000Z - 5 weeks ago

Viridian Therapeutics price target raised to $35 from $34 at RBC Capital

Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs

2026-06-30T11:10:27.000Z - 5 weeks ago

Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs

Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform

2026-06-29T13:30:08.000Z - 5 weeks ago

Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform

Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

2026-06-29T13:25:35.000Z - 5 weeks ago

Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

Viridian Therapeutics Transcript: FDA announcement

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Viridian Therapeutics Transcript: FDA announcement

Viridian Therapeutics Press release: FDA announcement

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Viridian Therapeutics Press release: FDA announcement

Viridian Therapeutics Slides: FDA announcement

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Viridian Therapeutics Slides: FDA announcement

Viridian Therapeutics announces FDA approval, launch of Lumvoa

2026-06-26T22:05:15.000Z - 5 weeks ago

Viridian Therapeutics announces FDA approval, launch of Lumvoa

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Jun 26, 2026, 6:00 PM EDT - 5 weeks ago

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 4:00 PM EDT - 2 months ago

Viridian Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Viridian Metals Commences 2026 Diamond Drill Program at the Kraken

Jun 9, 2026, 9:00 AM EDT - 2 months ago

Viridian Metals Commences 2026 Diamond Drill Program at the Kraken

Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program

Jun 5, 2026, 10:00 AM EDT - 2 months ago

Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program

Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 5:30 PM EDT - 2 months ago

Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Viridian Therapeutics Slides: Company presentation

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Viridian Therapeutics Slides: Company presentation

Viridian Therapeutics Slides: Corporate presentation

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Viridian Therapeutics Slides: Corporate presentation

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 27, 2026, 7:00 AM EDT - 2 months ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project

May 19, 2026, 1:30 PM EDT - 2 months ago

Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project

Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI

2026-05-15T12:28:02.000Z - 2 months ago

Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI

Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting

May 14, 2026, 11:43 AM EDT - 2 months ago

Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting

Viridian Therapeutics price target lowered to $39 from $48 at Stifel

2026-05-13T18:58:41.000Z - 2 months ago

Viridian Therapeutics price target lowered to $39 from $48 at Stifel

Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00

2026-05-07T11:24:55.000Z - 3 months ago

Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00

Viridian Therapeutics price target raised to $34 from $30 at RBC Capital

2026-05-07T06:49:01.000Z - 3 months ago

Viridian Therapeutics price target raised to $34 from $30 at RBC Capital

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

May 6, 2026, 11:13 PM EDT - 3 months ago

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

May 5, 2026, 4:05 PM EDT - 3 months ago

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Therapeutics Transcript: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Viridian Therapeutics Transcript: Study result

Viridian Therapeutics Press release: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Viridian Therapeutics Press release: Study result

Viridian Therapeutics Slides: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Viridian Therapeutics Slides: Study result

Viridian announces REVEAL-2 phase 3 study met primary endpoint

2026-05-05T11:38:18.000Z - 3 months ago

Viridian announces REVEAL-2 phase 3 study met primary endpoint

Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)

2026-05-05T11:26:55.000Z - 3 months ago

Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)

Viridian eye disease drug benefits chronic patients in late-stage trial

May 5, 2026, 7:05 AM EDT - 3 months ago

Viridian eye disease drug benefits chronic patients in late-stage trial

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 5, 2026, 7:01 AM EDT - 3 months ago

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

May 5, 2026, 7:00 AM EDT - 3 months ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Viridian Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:00 AM EDT - 3 months ago

Viridian Therapeutics Quarterly report: Q1 2026

Viridian Therapeutics Earnings release: Q1 2026

May 5, 2026, 7:00 AM EDT - 3 months ago

Viridian Therapeutics Earnings release: Q1 2026

Viridian Therapeutics Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 3 months ago

Viridian Therapeutics Slides: Corporate presentation

Viridian Therapeutics price target lowered to $33 from $36 at Truist

2026-04-21T15:48:24.000Z - 3 months ago

Viridian Therapeutics price target lowered to $33 from $36 at Truist

Viridian Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Viridian Therapeutics Proxy statement: Proxy filing

Viridian Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Viridian Therapeutics Proxy statement: Proxy filing

Viridian Therapeutics price target lowered to $24 from $32 at Evercore ISI

2026-04-13T13:57:38.000Z - 4 months ago

Viridian Therapeutics price target lowered to $24 from $32 at Evercore ISI

Viridian Therapeutics price target lowered to $36 from $40 at Truist

2026-04-08T12:32:05.000Z - 4 months ago

Viridian Therapeutics price target lowered to $36 from $40 at Truist

AMGN

Viridian Therapeutics price target lowered to $31 from $37 at Wedbush

2026-04-08T11:48:42.000Z - 4 months ago

Viridian Therapeutics price target lowered to $31 from $37 at Wedbush

AMGN

Viridian Therapeutics price target lowered to $30 from $42 at RBC Capital

2026-04-07T13:56:27.000Z - 4 months ago

Viridian Therapeutics price target lowered to $30 from $42 at RBC Capital

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

Apr 6, 2026, 12:10 PM EDT - 4 months ago

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

AMGN

Viridian Therapeutics Transcript: Study result

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Viridian Therapeutics Transcript: Study result

Viridian Therapeutics Press release: Study result

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Viridian Therapeutics Press release: Study result

Viridian Therapeutics Slides: Study result

Mar 30, 2026, 8:00 AM EDT - 4 months ago

Viridian Therapeutics Slides: Study result

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Mar 30, 2026, 7:01 AM EDT - 4 months ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Viridian Therapeutics Slides: Corporate presentation

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Viridian Therapeutics Slides: Corporate presentation

Viridian Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Viridian Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Viridian Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 5 months ago

Viridian Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:01 AM EST - 5 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Viridian Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Viridian Therapeutics Annual report: Q4 2025

Viridian Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Viridian Therapeutics Earnings release: Q4 2025

Viridian Therapeutics Slides: Corporate presentation

Feb 26, 2026, 6:00 AM EST - 5 months ago

Viridian Therapeutics Slides: Corporate presentation

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 4:01 PM EST - 7 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Prepares for Transformational 2026

Jan 6, 2026, 7:01 AM EST - 7 months ago

Viridian Therapeutics Prepares for Transformational 2026

Viridian Therapeutics Slides: Corporate Presentation

Jan 6, 2026, 7:00 AM EST - 7 months ago

Viridian Therapeutics Slides: Corporate Presentation

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Dec 22, 2025, 7:00 AM EST - 8 months ago

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Viridian Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 9:35 AM EST - 8 months ago

Viridian Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Viridian Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:00 AM EST - 9 months ago

Viridian Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Viridian Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 9:20 AM EST - 9 months ago

Viridian Therapeutics Transcript: Stifel 2025 Healthcare Conference

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 5, 2025, 7:01 AM EST - 9 months ago

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Viridian Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Viridian Therapeutics Quarterly report: Q3 2025

Viridian Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Viridian Therapeutics Earnings release: Q3 2025

Viridian Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 9 months ago

Viridian Therapeutics Slides: Corporate Presentation

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Nov 3, 2025, 7:01 AM EST - 9 months ago

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Oct 21, 2025, 11:24 PM EDT - 10 months ago

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Oct 21, 2025, 4:01 PM EDT - 10 months ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Oct 20, 2025, 7:30 AM EDT - 10 months ago

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Sep 15, 2025, 7:01 AM EDT - 11 months ago

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Viridian Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Viridian Therapeutics Earnings release: Q2 2025

Viridian Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Viridian Therapeutics Quarterly report: Q2 2025

Viridian Therapeutics Slides: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Viridian Therapeutics Slides: Q2 2025

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 6:30 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Jul 30, 2025, 4:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 8:40 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Viridian Therapeutics Slides: Corporate Presentation

Jun 5, 2025, 6:00 PM EDT - 1 year ago

Viridian Therapeutics Slides: Corporate Presentation

Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 7:35 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 20, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 7, 2025, 4:15 PM EDT - 1 year ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Quarterly report: Q1 2025

Viridian Therapeutics Earnings release: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Earnings release: Q1 2025

Viridian Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Proxy statement: Proxy Filing

Viridian Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Proxy statement: Proxy Filing

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Apr 7, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 12, 2025, 10:00 AM EDT - 1 year ago

Viridian Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Viridian Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:10 AM EST - 1 year ago

Viridian Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Annual report: Q4 2024

Viridian Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Earnings release: Q4 2024

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Jan 8, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Dec 16, 2024, 7:10 AM EST - 1 year ago

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Dec 16, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Dec 13, 2024, 6:00 PM EST - 1 year ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Nov 12, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Earnings release: Q3 2024

Viridian Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Quarterly report: Q3 2024

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Sep 11, 2024, 11:25 PM EDT - 2 years ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Sep 10, 2024, 4:01 PM EDT - 2 years ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Sep 10, 2024, 7:18 AM EDT - 2 years ago

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Sep 10, 2024, 7:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Sep 9, 2024, 4:01 PM EDT - 2 years ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:15 AM EDT - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Viridian Therapeutics Quarterly report: Q2 2024

Viridian Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Viridian Therapeutics Earnings release: Q2 2024

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 11, 2024, 8:40 AM EDT - 2 years ago

Viridian Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Jun 11, 2024, 6:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Proxy statement: Proxy Filing

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Proxy statement: Proxy Filing

Viridian Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 5:00 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 31, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics Transcript: Bank of America Health Care Conference 2024

May 15, 2024, 7:35 PM EDT - 2 years ago

Viridian Therapeutics Transcript: Bank of America Health Care Conference 2024

Viridian Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 8:30 AM EDT - 2 years ago

Viridian Therapeutics Transcript: 2024 RBC Capital Markets Global Healthcare Conference

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 10, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Earnings Call Transcript: Q1 2024

Viridian Therapeutics Quarterly report: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Quarterly report: Q1 2024

Viridian Therapeutics Earnings release: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Earnings release: Q1 2024

Viridian Therapeutics Slides: Q1 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Slides: Q1 2024

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

May 7, 2024, 7:33 PM EDT - 2 years ago

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

TheProphitWhisperer
TheProphitWhisperer Aug. 4 at 5:42 PM
$VRDN Will be back at $30 soon
0 · Reply
schmittzi
schmittzi Aug. 4 at 10:43 AM
$VRDN
0 · Reply
Merlintrader
Merlintrader Aug. 4 at 10:03 AM
Viridian Therapeutics (Nasdaq: $VRDN): Complete Stock Hub for FDA-Approved Lumvoa, Elegrobart and the TED Franchise https://www.merlintrader.com/viridian-therapeutics-stock-hub/
0 · Reply
Oldgrape
Oldgrape Aug. 4 at 7:13 AM
$VRDN Payor coverage is on track.. Even mildly ahead on speed I would say based on insurance documents posted as of today. CBS Michigan --> Lumvoa better than Tepezza (no site-of-care requirement & Tepezza has one) Humana IL D-SNP --> both free of step therapy Coordinated Care WA --> same class, same tier, no differential flags Centene Ambetter --> mutual exclusion Kaiser WA -->not yet written + already on PA list for Cigna, United Healthcare etc
3 · Reply
type12
type12 Aug. 3 at 4:35 PM
$VRDN https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrdn/viridian-therapeutics/news/how-positive-elegrobart-reveal-1-phase-iii-data-could-impact
0 · Reply
Oldgrape
Oldgrape Aug. 1 at 7:40 AM
$VRDN I have been reading facebook thyroid eye disease groups and see posts about patients with relapsed TED after TEPEZZA are being approved for Lumvoa. Earnings call should shed more light on this but if this early trend is true, this relapsed segment alone is a bilion plus opportunity that sits outside the active-TED market consensus models with zero competition.
1 · Reply
Grannynani
Grannynani Jul. 31 at 7:24 PM
$SOC $VRDN how I’m feeling rn. Shorted but gettin tall📈
0 · Reply
Grannynani
Grannynani Jul. 31 at 4:08 PM
$SOC greeaaaat 10% pull starting todayyyy📈🙏🏼. $VRDN Ouuu if you was in front of me of me I’d slap the shit out you📉🤨 stop being goofy and invest in the certified biotech who actually has a drug competing and beating a big name pharma👀 and we goin downnnn🤦🏻‍♂️ need a Michael Jackson ahhh slap🕺🏼👋🏼
0 · Reply
TheProphitWhisperer
TheProphitWhisperer Jul. 30 at 3:18 PM
$VRDN Nice consolidation before a breakout in anticipation of the August 4th earnings.
0 · Reply
schmittzi
schmittzi Jul. 30 at 2:44 PM
$VRDN
0 · Reply
Biotechinves
Biotechinves Jul. 30 at 1:18 PM
$VRDN
0 · Reply
Grannynani
Grannynani Jul. 29 at 8:52 PM
$SOC $VRDN my 2 favorite stocks atm even though they are dragging their asses rn. I’ll keep buying in the green and red. $VRDN growing child waiting for a growth spurt. Hopefully August 4th hits us gooood🙏🏼. And $SOC my wild one took some hits but getting back up for sure. BULLISH📈🐂
0 · Reply
StockConsultant
StockConsultant Jul. 28 at 1:18 PM
$VRDN Viridian Therapeutics stock, watch for an upside gap breakout at https://stockconsultant.com/?VRDN Breakout trade WATCH for possible breakout above 20.41 Target: 22.82, 15.8% Stop: 18.88 Loss: 4.2% P/L ratio: 3.8 : 1 - Excellent BULLISH [Timing] Strong bullish 3 day candlestick pattern with Average 3 day accumulation. [Timing] breakout watch above 20.41, no resistance in area just above. BEARISH [Positioning] at resistance
0 · Reply
options1315
options1315 Jul. 26 at 3:56 PM
$VRDN bearish
0 · Reply
Biotechinves
Biotechinves Jul. 26 at 3:32 PM
$VRDN
0 · Reply
Biotechinves
Biotechinves Jul. 26 at 10:31 AM
$VRDN next earning will be the pivot. If they proved themselves, it could double in a year more or less.
0 · Reply
schmittzi
schmittzi Jul. 21 at 11:26 AM
$VRDN
0 · Reply
CDMO
CDMO Jul. 20 at 6:56 PM
$VRDN weird strength today, probably BO tomorrow 🤡
2 · Reply
CDMO
CDMO Jul. 20 at 5:18 PM
$VRDN 🧨
0 · Reply
Grannynani
Grannynani Jul. 20 at 12:12 AM
Just topped up on some $VRDN very excited for earning day August 5th. Hopefully that’ll start us up. Also grabbed some $SOC Any stocks I should be looking into that y’all are favoring any input is always great. Let’s start this week off BULLISH🤌🏼📈🐂💰
1 · Reply
SoYeonPicks
SoYeonPicks Jul. 18 at 6:22 AM
$VRDN take this back above 20 next week
0 · Reply
Motohead125
Motohead125 Jul. 18 at 5:53 AM
$VRDN so we gon b rich or what?
0 · Reply